【Luncheon Symposium 5】

Insights from Global Phase 3 Trials: Vadadustat in Anemia Treatment for CKD Patients on Dialysis

Steven K. Burke

Senior Vice President, Research & Development and Chief Medical Officer Akebia Therapeutics

As the prevalence of chronic kidney disease (CKD) continues to increase worldwide, particularly in populations requiring dialysis, managing anemia effectively has become an urgent clinical priority. Anemia, a common complication in CKD, contributes to significant patient morbidity and impacts the overall quality of life for individuals undergoing dialysis. Traditionally, erythropoiesis-stimulating agents (ESAs), such as Darbepoetin alfa, have been the standard treatment for managing anemia in CKD patients. However, frequent injections and variability in response, especially among patients with inflammation, pose ongoing challenges to the use of ESA therapy. In this context, Vadadustat, an innovative oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), offers a promising new approach for treating anemia in dialysis- dependent CKD patients.

Global Phase 3 trials, including the pivotal INNO2VATE study, have extensively investigated the safety and efficacy of Vadadustat in comparison to established ESA treatments. The INNO2VATE trial results reveal that Vadadustat successfully maintains hemoglobin (Hb) levels within target ranges in dialysis patients, achieving efficacy outcomes that are non-inferior to Darbepoetin alfa, a widely used ESA. This efficacy was observed in primary assessment periods (weeks 24 to 36) and sustained through secondary evaluation periods (weeks 40 to 52), showcasing the drug's ability to deliver consistent therapeutic effects over time. Notably, HIF-PHi demonstrated these outcomes even in patients with inflammation—a common condition among CKD patients on dialysis, which often renders traditional ESA treatments less effective.

The safety profile of Vadadustat has also been rigorously evaluated. In terms of cardiovascular safety, one of the critical concerns in CKD treatment, Vadadustat showed non-inferiority to Darbepoetin alfa in terms of major adverse cardiovascular events (MACE). Specifically, the hazard ratio for MACE in patients treated with Vadadustat was 0.96, with a 95% confidence interval (CI) ranging from 0.83 to 1.11, indicating a similar risk profile to Darbepoetin alfa in this vulnerable population. This safety outcome underscores Vadadustat’s potential as a reliable alternative to traditional injectable therapies.

Vadadustat's development and promising clinical trial results represent an exciting advancement in the management of anemia for dialysis-dependent CKD patients. The convenience of an oral formulation addresses one of the significant barriers to compliance associated with injection therapies, potentially enhancing patient adherence and quality of life. Furthermore, Vadadustat's consistent efficacy in inflammatory conditions broadens its applicability to patients who might be hyporesponsive to ESAs, offering a new, viable treatment strategy for a subset of patients who are difficult to manage with conventional therapies.

Overall, the insights from these Phase 3 global trials position Vadadustat as a valuable addition to the therapeutic options for managing dialysis-related anemia, giving healthcare providers a novel tool to improve patient outcomes and reduce the burden of frequent injections. As the landscape of CKD management evolves, Vadadustat's profile as an effective, oral alternative to ESAs could play a significant role in enhancing the quality of care for patients with anemia associated with dialysis.